Trials / Completed
CompletedNCT05031832
Chemsex Engagement and HIV Biomedical Prevention in MSM
The Interrelationship Between Chemsex Engagement and HIV Biomedical Prevention in MSM
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 733 (actual)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
HIV biomedical prevention through treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP) is highly efficacious for reducing HIV transmission risk. The benefits could be undermined by the rising HIV transmission risks in men who have sex with men (MSM) who engaged in chemsex. This project aims to assess the impacts of chemsex on the growth of the HIV epidemic by exploring the complex relationships between chemsex engagement and usage of HIV biomedical prevention in MSM in Hong Kong. Participants would be recruited from the community and clinics in 2 cross-sectional studies (500 HIV-negative and 500 HIV-positive MSM), for HIV self-testing and completing an electronic questionnaire. The association of chemsex would be examined between PrEP-naïve and PrEP experienced HIV-negative MSM, and between good and poor adherence to antiretroviral therapy (ART) among HIV-positive subjects in case-control analyses using logistic regression and multilevel models. The main outcomes include coverage of biomedical prevention in MSM, and their drug use patterns.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | HIV test | HIV test would be offered to self-reported HIV-negative / unknown HIV status MSM to confirm their HIV status |
Timeline
- Start date
- 2021-06-01
- Primary completion
- 2024-10-02
- Completion
- 2024-12-31
- First posted
- 2021-09-02
- Last updated
- 2025-01-23
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT05031832. Inclusion in this directory is not an endorsement.